Listed by the USPTO as STAVROU, CONSTANTINA E
Tech Center 1600 • Art Units: 1632 1678
This examiner grants 42% of resolved cases
STAVROU, CONSTANTINA E is assigned to tech center 1600 and art unit 1632. The record includes 93 resolved cases, with an allowance rate of 41.9%. The interview lift is 36.1%, and the median time to allowance is 1428 days. The figures show a limited examination history, a relatively low allowance outcome, and a substantial measured interview association.
Massachusetts Institute of Technology, University Health Network, and The Brigham and Women's Hospital Inc. are the leading companies or institutions listed. The firms are Johnson, Marcou, Isaacs & Nix, LLC, WC&F IP, and Xsensus. Practitioners may prioritize interviews that explain the technical contribution, while preparing detailed written distinctions and multiple amendment routes for the extended prosecution timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18572723 | ADENO-ASSOCIATED VIRAL (AAV) VECTORS FOR TISSUE-TARGETED EXPRESSION OF THERAPEUTIC GENES | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | Non-Final OA | Novartis AG |
| 18042040 | PROCESS SYSTEM FOR BIOREACTOR-BASED CLEAN MEAT PRODUCTION | Final Rejection | Merck Patent GmbH |
| 18701358 | RNA-GUIDED TRANS-SPLICING OF RNA | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 16707681 | PRE-SHAPED ALLOGRAFT IMPLANT FOR RECONSTRUCTIVE SURGICAL USE AND METHODS OF MANUFACTURE AND USE | Non-Final OA | Allosource |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | Final Rejection | ImmunityBio, Inc. |
| 18685660 | METHODS FOR PRODUCTION OF ENGINEERED CELLS | Non-Final OA | Centre National de la Recherche Scientifique |
| 17545416 | METHODS FOR CONTROLLED INDUCTION OF BIOENGINEERED NEUROEPITHELIAL TISSUES AND 3-D NEUROEPITHELIAL TUBES | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18690594 | SALMONELLA ENGINEERED FOR NONTOXIC COLONIZATION OF TUMORS | Non-Final OA | Regents of the University of Minnesota |
| 17571802 | Methods for cryopreservation of sub-millimeter and millimeter scale biological materials | Non-Final OA | Regents of the University of Minnesota |
| 16632332 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 17282117 | MODULAR BIOFABRICATION PLATFORM FOR DIVERSE TISSUE ENGINEERING APPLICATIONS AND RELATED METHOD THEREOF | Non-Final OA | University of Virginia Patent Foundation |
| 18252714 | ECTOPIC CELLULAR GROWTH FACTOR EXPRESSION FOR LOW-COST PRODUCTION OF CELL-CULTURED FOODS | Final Rejection | Trustees of Tufts College |
| 16975987 | NANOPATTERNING FOR CONTROLLING CELL CYTOSKELETON | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18642228 | METHODS OF PRODUCING TENDON NEOTISSUE FROM ADULT STEM CELLS AND USES THEREOF | Non-Final OA | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College |
| 18023289 | COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 17867335 | COMPOSITIONS AND METHODS FOR GENERATION OF RETINAL GANGLION CELLS FROM INDUCIBLE PLURIPOTENT STEM CELLS FOR THE TREATMENT OF PROGRESSIVE OPTIC NEUROPATHIES, INCLUDING GLAUCOMA | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18837739 | COMPOSITIONS AND METHODS FOR EXPANDING LYMPHOCYTES | Non-Final OA | StemCell Technologies Canada Inc. |
| 18559577 | METHOD OF MANUFACTURING ALVEOLAR ORGANOID USING ALVEOLAR CELL-DERIVED INDUCED PLURIPOTENT STEM CELLS | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17600348 | CELL CONSTRUCT AND CELL CONSTRUCT PRODUCTION METHOD | Final Rejection | Kyoto Prefectural Public University Corporation |
| 18562448 | SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS | Non-Final OA | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.9% of resolved applications examined by Constantina E Stavrou were allowed (93 resolved cases), compared with 38.0% across Art Unit 1632 over the last five years.
This examiner's interview lift is +36.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Constantina E Stavrou took 1,428 days on average from filing to allowance.
Constantina E Stavrou examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).